Diageo and Brown-Forman both face weakening alcohol demand, with U.S. drinking participation down to 54% and their shares falling 64% and 69% over five years, respectively. Diageo posted FY2025 revenue of $20.2B and net margin of 11.6%, while Brown-Forman generated $4.0B of revenue and a higher 21.9% net margin, but both appear cheaply valued at 17.0x and 15.2x forward P/E. The article is cautious overall, preferring to wait for improved sales, though it would favor Diageo on scale, international exposure, and a 4.2% dividend yield.
This is less a “which is cheaper” debate than a question of which business has a cleaner path to mean reversion. DEO’s bigger issue is operating leverage: when volumes soften, a globally diversified portfolio can still see margin compression if it is forced to defend shelf space and fund brand support across too many geographies at once. BF.B looks financially sturdier, but that stability is partly illusory because a concentrated brand mix means any loss of relevance in a handful of whiskey franchises can hit both growth and bargaining power simultaneously.
The second-order winner is likely competitors with stronger route-to-market optionality, not necessarily the two names in the article. If U.S. drinking participation keeps drifting lower, premiumization becomes harder to sustain and distributors will favor suppliers with broader price ladders and faster innovation cycles; that structurally favors larger spirits portfolios and adjacent staples names over single-family-brand models. Trade policy is the hidden swing factor: tariff relief would help BF.B’s international margin more than the market expects, while any escalation would reinforce DEO’s geographic diversification advantage and likely widen the valuation gap in DEO’s favor.
Catalyst timing matters: over the next 1-3 quarters, this is a “prove it” market where neither stock should rerate without visible stabilization in organic sales and margin cadence. The current setup looks like a low-volatility value trap unless management can show either accelerating mix improvement or credible capital return support. The more interesting upside asymmetry is in DEO, because a modest recovery in sales can re-rate a larger revenue base and make the dividend/FCF yield screen much more compelling than BF.B’s lower absolute valuation multiple.
Consensus may be underestimating how much bad news is already discounted in both names, especially after multi-year de-rating. That said, the market is likely still too optimistic about a quick rebound in alcohol demand among younger consumers; if that weakness is structural, these stocks may deserve a lower terminal multiple than history implies. The better contrarian angle is not to buy the stocks outright, but to own optionality on a stabilization event while avoiding full equity beta until the next two earnings prints confirm the trend.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment